OnDemand WTP Pricing Research

Five Questions About Price Transparency [Video] | AAF

This week, Christopher Holt explains in a brief video the intention behind encouraging price transparency in health care — as well as the challenges that come with such transparency.

CHART REVIEW
Tara O’Neill Hayes, Deputy Director of Health Care Policy

Congress is considering reforms to the Medicare Part D benefit structure, including potentially changing the point in the program when drug manufactures must pay rebates for brand-name drugs and how much of a rebate must be paid. The following chart shows the amount of the rebate that would be required under various proposals, as well as the amount currently required by law, based on a drug’s price. The size of the bubble represents the amount of the rebate as a percentage of the drug’s price.

Read complete article here:

Five Questions About Price Transparency – AAF.

Post a Comment

WP-SpamFree by Pole Position Marketing